InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,544.59
(
-0.78%
)
US TECH 100
19,234.40
(
-0.19%
)
Dow Jones
40,665.02
(
-1.29%
)
Brent Oil
83.94
(
-0.17%
)
Bitcoin
64,256.44
(
0.45%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: nmstav post# 4355

Friday, 06/22/2007 12:51:43 AM

Friday, June 22, 2007 12:51:43 AM

Post# of 12660
I think you can pretty much narrow your simulation "window" to patients receiving taxotere following progression from 9902B rather than other investigational agents such as the CTLA-4 blockers. Most trials for non-approved drugs will have exclusion criteria relating to prior investigational drug treatment, making Provenge treated patients ineligible.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up